Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Ibrutinib—a new standard treatment for relapsed mantle cell lymphoma?

In The Lancet, Martin Dreyling and colleagues1 present the results of a large, international, randomised phase 3 trial comparing the only two drugs approved for previously treated mantle cell lymphoma in Europe: temsirolimus and ibrutinib. Among 280 patients, those randomly assigned to daily oral ibrutinib 560 mg (n=139) showed a significant improvement in progression-free survival, the trial’s primary endpoint, compared with patients (n=141) assigned to daily intravenous temsirolimus 175 mg (14·6 months vs 6·2 months; hazard ratio 0·43 [95% CI 0·32–0·58]).